Altered brain serotonin homeostasis and locomotor insensitivity to 3,4- methylenedioxymethamphetamine ('ecstasy') in serotonin transporter-deficient mice

Molecular Pharmacology

Volumn 53, Issue 4, 1998, Pages 649-655

  Bengel, Dietmar ^a   Murphy, Dennis L ^a   Andrews, Anne M ^a   Wichems, Christine H ^a   Feltner, Douglas ^b   Heils, Armin ^c   Mössner, Rainald ^c   Westphal, Heiner ^b   Lesch, Klaus Peter ^c  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; AMPHETAMINE; FLUOXETINE; PAROXETINE; SEROTONIN; SEROTONIN TRANSPORTER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CONTROLLED STUDY; FEMALE; GENOTYPE; HYPERACTIVITY; INTRAPERITONEAL DRUG ADMINISTRATION; KNOCKOUT MOUSE; LOCOMOTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEROTONIN BRAIN LEVEL;

EID: 0031978809     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.53.4.649     Document Type: Article

References (45)

1. Andrews AM and Murphy DL (1993) Sustained depletion of cortical and hippocampal serotonin and norepinephrine but not striatal dopamine. J Neurochem 60: 1167-1170.
2. Barker EL, Moore KR, and Blakely RD (1997) A conserved aspartate in TMD 1 interacts with substrates of the monoamine neurotransmitter transporters. Soc Neurosci Abstr 23:1131.
3. Bengel D, Heils A, Petri S, Seemann M, Glatz K, Andrews A, Murphy DL, and Lesch KP (1997) Gene structure and 5′-flanking regulatory region of the murine serotonin transporter. Mol Brain Res 44:286-292.
4. Blakely R, De Felice LJ, and Hartzell HC (1994) Molecular physiology of norepinephrine and serotonin transporters. J Exp Biol 196:263-281.
5. Cabrera-Vera TM, Garcia F, Pinto W, and Battaglia G (1997) Effect of prenatal fluoxetine (Prozac) exposure on serotonin neurons in prepubescent and adult male rat offspring. J Pharmacol Exp Ther 280:138-145.
6. Callaway CW, Wing LL, and Geyer MA (1990) Serotonin release contributes to the locomotor stimulant effects of 3,4-methylenedioxymethamphetamine in rats. J Pharmacol Exp Ther 254:456-464.
7. Cases O, Vitalis T, Seif I, De Maeyer E, Sotelo C, and Gaspar P (1996) Lack of barrels in the somatosensory cortex of monoamine oxidase A-deficient mice: role of a serotonin excess during the critical period. Neuron 16:297-307.
8. Chambers CD, Johnson KA, Dick LM, Felix RJ, and Jones KL (1996) Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 335:1010-1015.
9. Feenstra MGP, Van Galen H, Te Riele PJM, Botterblom MHA, and Mirmiram M (1996) Decreased hypothalamic serotonin levels in adult rats treated with clomipramine. Pharmacol Biochem Behav 55:647-652.
10. Giros B, Jaber M, Jones SR, Wightman RM, and Caron MG (1996) Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature (Lond) 379:606-612.
11. Green AR, Cross AJ, and Goodwin GM (1995) Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy"). Psychopharmacology 119:247-260.
12. Griebel G (1995) 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: more than 30 years of research. Pharmacol Ther 65:319-395.
13. Gudelsky GA and Nash JF (1996) Carrier-mediated release of serotonin by 3,4-methylenedioxymethamphetamine: implications for serotonin-dopamine interactions. J Neurochem 66:243-249.
14. Kelly PH and Iversen SD (1976) Selective 6-OHDA-induced destruction of mesolimbic dopamine neurons: abolition of psychostimulant-induced locomotor activity in rats. Eur J Pharmacol 40:45-56.
15. Koob GF, Stinus L, and Le Moal M (1981) Hyperactivity and hypoactivity produced by lesions to the mesolimbic DA system. Behav Brain Res 3:341-359.
16. Lebrand C, Cases O, Adelbrecht C, Doye A, Alvarez C, El Mestikawy S, Seif I, and Gaspar P (1996) Transient uptake and storage of serotonin in developing thalamic neurons. Neuron 17:823-835.
17. Lesch KP, Aulakh CS, and Murphy DL (1993a) Brain serotonin subsystem complexity and receptor heterogeneity: therapeutic potential of selective serotonin agonists and antagonists, in Clinical Pharmacology in Psychiatry: Strategies in Psychotropic Drug Development (Gram LF, ed) pp 52-69, Springer-Verlag, Berlin.
18. Lesch KP, Wolozin BL, Estler HC, Murphy DL, and Riederer P (1993b) Isolation of a cDNA encoding the human brain serotonin transporter. J Neural Transm Gen Sect 91:67-72.
19. Lesch KP, Balling U, Gross J, Strauss K, Wolozin BL, Murphy DL, and Riederer P (1994) Organization of the human serotonin transporter gene. J Neural Transm Gen Sect 95:157-162.
20. Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, Benjamin J, Müller CR, Hamer DH, and Murphy DL (1996) Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science (Washington DC) 274:1527-1531.
21. Levi G and Raiteri MT (1993) Carrier mediated release of neurotransmitters. Trends Neurosci 16:415-419.
22. Maarten EA and O'Reilly CA (1990) Inhibition of serotonin uptake into mouse brain synaptosomes by ionophores and ion-channel agents. Brain Res 521:347-351.
23. Melo JA, Shendure J, Pociask K, and Silver LM (1996) Identification of sex-specific quantitative trait loci controlling alcohol preference in C57BL/6 mice. Nat Genet 13:147-153.
24. Moiseiwitsch JR and Lauder JM (1995) Serotonin regulates mouse cranial neural crest migration. Proc Natl Acad Sci USA 92:7182-7186.
25. Murphy DL, Greenberg BD, Altemus M, Benjamin J, Grady T, and Pigott T (1996) The neuropharmacology and neurobiology of obsessive-compulsive disorder: an update on the serotonin hypothesis, in Advances in the Neurobiology of Anxiety Disorders (Westenberg HGM, ed) pp 279-297, Wiley Publications, New York.
26. Nulman I, Rovet J, Stewart DE, Wolpin J, Gardner HA, Theis JG, and Kulin N (1997) Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 336:258-262.
27. Olson EN, Arnold HH, Rigby PW, and Wold BJ (1996) Known neighbors: three phenotypes in null mutants of the myogenic bHLH gene MRF 4. Cell 85:1-4 .
28. Owens MJ and Nemeroff CB (1994) Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clin Chem 40:288-295.
29. Qian Y, Galli A, Ramamoorthy S, Risso S, DeFelice LJ, and Blakely RD (1997) Protein kinase C activation regulates human serotonin transporters in HEK-293 cells via altered cell surface expression. J Neurosci 17:45-57.
30. Rattray M (1991) Ecstasy: towards an understanding of the biochemical basis of the action of MDMA. Essays Biochem 26:77-87.
31. Robert E (1996) Treatment depression in pregnancy [editorial comment on N Engl J Med 335:1010-1015 (1996) N Engl J Med 335:1056-1058.
32. Rudnick G and Wall SC (1992) The molecular mechanism of "ecstasy " (3,4-methylenedioxymethamphetamine, MDMA: serotonin transporters are targets for MDMA induced serotonin release. Proc Natl Acad Sci USA 89:1817-1821.
33. Schmidt CJ, Levin JA, and Lovenberg W (1987) In vitro and in vivo neurochemical effects of methylenedioxymethamphetamine on striatal monoaminergic systems in the rat brain. Biochem Pharmacol 36:747-55.
34. Shuey DL, Sadler TW, and Lauder JM (1992) Serotonin as a regulator of craniofacial morphogenesis: site specific malformations following exposure to serotonin uptake inhibitors. Teratology 46:367-378.
35. Sidman RL, Angevine JB, and Pierce ET (1971) Atlas of the Mouse Brain and Spinal Cord. Harvard University Press, Cambridge, MA.
36. 125I]RTI-55 associated with the 5-HT transporter in rat brain membranes. J Pharmacol Exp Ther 273:213-222.
37. Steele TD, McCann UD, and Ricaurte GA (1994) 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy"): pharmacology and toxicology in animals and humans Addiction 89:539-551.
38. Tybulewicz VL, Crawford CE, Jackson PK, Bronson RT, and Mulligan RC (1991) Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-alb proto-oncogene. Cell 65:1153-1163.
39. Vanhoutte PM, Saxena PR, Paoletti R, Brunello N, Jackson N, and Jackson AS (1993) Serotonin: From Cell Biology to Pharmacology and Therapeutics. Kluwer Academic, Dordrecht, The Netherlands.
40. Vorhees CV, Acuff-Smith KD, Schilling MA, Fisher JE, Moran MS, and Buelke-Sam JA (1994) A developmental neurotoxicity evaluation of the effects of prenatal exposure to fluoxetine in rats. Fundam Appl Toxicol 23:194-205.
41. Walters ET, Carew TJ, and Kandel ER (1981) Associative learning in aplysia: evidence for conditioned fear in an invertebrate. Science (Washington DC) 211: 504-506.
42. White SR, Obradovic T, Imel KM, and Wheaton MJ (1996) The effects of methylenedioxymethamphetamine (MDMA, "Ecstasy") on monoaminergic neurotransmission in the central nervous system. Prog Neurobiol 49:455-479.
43. Wichems CH, Hollingsworth CK, and Bennett BA (1995) Release of serotonin induced by 3,4-methylenedioxymethamphetamine (MDMA) and other substituted amphetamines in cultured fetal raphe neurons: further evidence for calcium-independent mechanisms of release. Brain Res 695:10-18.
44. Yavarone MS, Shuey DL, Tamir H, Sadler TW, and Lauder JM (1993) Serotonin and cardiac morphogenesis in the mouse embryo. Teratology 47:573-584.
45. Yeh SR, Fricke RA, and Edwards DH (1996) The effect of social experience on serotonergic modulation of the escape circuit of crayfish. Science (Washington DC) 271:366-369.